Nasdaq

Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis

INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus ...
WFMZ-TV

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis | Tds | wfmz.com

INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b /4 SPIRIT-Head-to-Head (H2H) study of Taltz ® (ixekizumab) versus ...
Nasdaq

ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis

INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented detailed results today demonstrating Taltz® (ixekizumab) met the primary and all major secondary endpoints in ...
Ibj.com

Lilly reports strong fourth quarter on rising sales of Trulicity, Taltz

Eli Lilly and Co., boosted by strong sales of diabetes drug Trulicity and psoriasis therapy Taltz, reported a fourth-quarter profit of $1.5 billion on Thursday, topping market expectations. The ...